Transgene Biotek Ltd
TRABITransgene Biotek Ltd
TRABI
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -203.95 | 4.76 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.70 | 6.31 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Transgene Biotek is a biotechnology company which operates transgene medical centers. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics
Peers
Compare with peersBiocon Ltd
Panacea Biotec Ltd
Hester Biosciences Ltd
Zenotech Laboratories Ltd
Vivo Bio Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.35 | 0.94 | 7.49 | 2.11 | 0.18 | 0.44 | 0.30 | 0.24 | 0.41 | 0.99 | ||||||||||
Raw Materials | 0.00 | 0.00 | 0.03 | 0.03 | 0.01 | 0.06 | -0.05 | 0.07 | 0.00 | 1.06 | ||||||||||
| Power & Fuel Cost | 0.10 | 0.12 | 0.06 | 0.06 | 0.16 | 0.01 | 0.01 | 0.01 | 0.00 | |||||||||||
| Employee Cost | 0.68 | 0.55 | 0.33 | 0.25 | 0.29 | 0.25 | 0.29 | 0.30 | 0.31 | |||||||||||
| Selling & Administrative Expenses | 0.47 | 0.20 | 0.25 | 0.35 | 0.37 | 0.27 | 0.27 | 0.27 | 0.48 | |||||||||||
| Operating & Other expenses | 0.06 | 1.97 | 1.54 | 0.05 | 0.03 | 0.10 | 0.02 | 0.02 | 0.05 | |||||||||||
EBITDA | -0.96 | -1.90 | 5.28 | 1.37 | -0.68 | -0.25 | -0.24 | -0.43 | -0.43 | -0.07 | ||||||||||
| Depreciation/Amortization | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.08 | ||||||||||
| PBIT | -21.46 | -19.43 | -4.61 | -8.52 | -10.58 | -10.16 | -10.16 | -5.38 | -0.52 | -0.15 | ||||||||||
| Interest & Other Items | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.10 | ||||||||||
| PBT | -21.53 | -19.86 | -5.64 | -8.78 | -10.96 | -10.43 | -10.39 | -6.00 | -0.66 | -0.25 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | -21.53 | -19.86 | -6.43 | -8.78 | -10.96 | -10.43 | -10.39 | -6.00 | -0.66 | -0.25 | ||||||||||
| EPS | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.03 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Transgene Biotek Ltd | -77.26 | 4.76 | — |
| Biocon Ltd | 38.30 | 1.55 | 0.15% |
| Panacea Biotec Ltd | -2,064.01 | 2.86 | — |
| Hester Biosciences Ltd | 109.80 | 6.84 | 0.25% |
Price Comparison
Compare TRABI with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.32%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
TRABI has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet Loss of Transgene Biotek reported to Rs 0.07 crore in the quarter ended September 2024 as against net loss of Rs 0.13 crore during the previous quarter ended September 2023. Sales rose 20.00% to Rs 0.06 crore in the quarter ended September 2024 as against Rs 0.05 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales0.060.05 20 OPM %-116.67-240.00 - PBDT-0.05-0.11 55 PBT-0.07-0.13 46 NP-0.07-0.13 46 Powered by Capital Market - Live
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
Net profit of Transgene Biotek reported to Rs 0.20 crore in the quarter ended June 2024 as against net loss of Rs 0.13 crore during the previous quarter ended June 2023. Sales declined 50.00% to Rs 0.05 crore in the quarter ended June 2024 as against Rs 0.10 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales0.050.10 -50 OPM %-820.00-120.00 - PBDT0.22-0.11 LP PBT0.20-0.13 LP NP0.20-0.13 LP Powered by Capital Market - Live
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
Transgene Biotek reports consolidated net loss of Rs 2.60 crore in the September 2021 quarter
Transgene Biotek reports consolidated net loss of Rs 2.61 crore in the June 2021 quarter
Transgene Biotek reports consolidated net loss of Rs 2.61 crore in the March 2021 quarter
Transgene Biotek reports consolidated net loss of Rs 2.52 crore in the December 2020 quarter
BRIEF-Transgene Biotek Says Board Approves Licensing Of TrabiORAL To GVK Bio - Investing.com India
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -27.94%, vs industry avg of 19.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.03% to 0%